Sintilimab in combination with anlotinib in non-small cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study

被引：0
|
作者：
Chen, K. [1 ]
Fan, Y. [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Oncol, Canc Hosp, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
    Bian, Dongliang
    Ji, Shuyu
    Liu, Yue
    Huang, Zhida
    Jiang, Lei
    Liu, Ming
    Bao, Xiao
    Yang, Jie
    Zhou, Yirui
    Hu, Junjie
    Sun, Liangdong
    Zheng, Yingzhi
    Huang, Jie
    Liu, Jing
    Zhu, Xinsheng
    Zhang, Jing
    Zhang, Lele
    Liu, Xiaogang
    He, Wenxin
    Xie, Dong
    Zhu, Yuming
    Wu, Chunyan
    Zhao, Deping
    Duan, Liang
    Jiang, Gening
    Zhang, Peng
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [32] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [33] Apatinib combined with irinotecan in the treatment of small cell lung cancer: A phase II, single-arm, prospective study
    Zhao, Y.
    Guo, L.
    Pu, H.
    Bai, S.
    Yang, M.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1043 - S1043
  • [34] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Xiong, Liwen
    Li, Rong
    Sun, Jiayuan
    Lou, Yuqing
    Zhang, Weiyan
    Bai, Hao
    Wang, Huiming
    Shen, Jie
    Jing, Bo
    Shi, Chunlei
    Zhong, Hua
    Gu, Aiqin
    Jiang, Liyan
    Shi, Jianxing
    Fang, Wentao
    Zhao, Heng
    Zhang, Jie
    Wang, Junyuan
    Ye, Junyi
    Han, Baohui
    ONCOLOGIST, 2019, 24 (02): : 157 - +
  • [35] PHASE II SINGLE-ARM STUDY OF PREOPERATIVE PEMETREXED (P) PLUS CISPLATIN (C) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Chabowski, M.
    Ramlau, R.
    Dyszkiewicz, W.
    Chouaki, N.
    Soldatenkova, V.
    Varea, R.
    Barriga, S.
    Visseren-Grul, C. M.
    Orlowski, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 395 - 395
  • [36] Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
    Lu, S.
    Fang, J.
    Liu, A.
    Dong, X.
    Yu, Y.
    Han, S.
    Zeng, Z.
    Zhang, R.
    Lu, P.
    Shi, H.
    Tan, P.
    Fan, S.
    Shi, M.
    Su, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1656
  • [37] Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
    Wang, Victoria E.
    Gainor, Justin F.
    JAMA ONCOLOGY, 2024, 10 (01) : 52 - 53
  • [38] Anlotinib Plus Toripalimab as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer: a Single-Arm Phase II Study
    Lv, D.
    Wu, G.
    Lin, L.
    Yan, S.
    Wu, X.
    Pan, W.
    Huang, J.
    Gao, Z.
    Gu, Q.
    Li, H.
    Chen, Q.
    Lin, W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S533 - S533
  • [39] Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
    Li, Hong-Shuai
    Yang, Guang-Jian
    Cai, Yi
    Li, Jun-Ling
    Xu, Hai-Yan
    Zhang, Tao
    Zhou, Li-Qiang
    Wang, Yu-Ying
    Wang, Jin-Liang
    Hu, Xing-Sheng
    Yan, Xiang
    Wang, Yan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Anlotinib in elderly patients with advanced non-squamous non-small cell lung cancer (NSCLC) who had not received systemic chemotherapy: A single-arm, multi-center, phase II study
    Zhao, D.
    Hou, X.
    Li, Z.
    Yang, L.
    Hou, X.
    Li, H.
    Yan, L.
    Liu, H.
    Li, Z.
    Liu, X.
    Song, F.
    Li, G.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1022 - S1022
12345